TuHURA Biosciences Set to Impress at Canaccord Genuity's Growth Conference in Boston

TuHURA Biosciences Presents at Canaccord Genuity's Annual Growth Conference

On August 12, 2026, TuHURA Biosciences, Inc. (NASDAQ:HURA), a pioneering company in immuno-oncology, will capture the attention of investors and industry experts at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA. James A. Bianco, M.D., the President and CEO of TuHURA, will lead the presentation, sharing insights on the company's revolutionary therapies aimed at combatting cancer immunotherapy resistance. This moment is crucial not only for the company but also for understanding the future landscape of cancer treatment.

TuHURA's Breakthrough in Cancer Therapy

TuHURA Biosciences is dedicated to developing novel therapeutic agents that specifically tackle the significant issue of resistance in cancer therapies, which has been a major hurdle in effective treatment. The company's flagship product, IFx-2.0, is an innate immune agonist designed to target and overcome primary resistance mechanisms associated with checkpoint inhibitors—a common form of immunotherapy that many patients rely on.

Currently, TuHURA is actively enrolling patients in a Phase 3 randomized placebo-controlled trial to evaluate IFx-2.0 when administered alongside Keytruda® (pembrolizumab), aimed at first-line treatment for advanced or metastatic Merkel Cell Carcinoma (MCC). This pivotal trial sets the stage for major advancements in treating patients with MCC, who have limited options available.

Expanding Horizons: The Future of Immuno-Oncology

In addition to its lead product, TuHURA is developing a second candidate, TBS-2025, an innovative monoclonal antibody inhibiting VISTA, which is set to enter Phase 1b trials. This treatment is particularly focused on a defined subgroup of patients with molecular abnormalities, specifically targeting those with Mutated NPM1 positive relapsed/refractory Acute Myeloid Leukemia (AML). It is projected that nearly 35% of AML patients fall within this category, indicating a substantial patient base for TBS-2025.

Alongside these therapies, TuHURA is also harnessing its unique Delta Opioid Receptor technology to craft bi-specific antibody-drug conjugates (ADCs). These novel treatments seek to negate the immune-suppressing activities of Myeloid-Derived Suppressor Cells (MDSCs), significantly boosting the efficacy of existing checkpoint inhibitors and cellular therapies.

Accessing the Conference and Future Insights

Attendees of the Canaccord Genuity Annual Growth Conference will be able to view Dr. Bianco's presentation live, and an archived version will be accessible on TuHURA's Investor Relations website afterward. In addition, interested stakeholders are encouraged to participate in a Q&A session featuring Dr. Bianco, designed to foster dialogue and engagement regarding TuHURA’s future direction and ongoing projects.

As the landscape of cancer therapy continues to evolve, TuHURA's groundbreaking work puts it at the forefront of innovation in this critical field. The upcoming conference represents not only a highlight for the company but also a crucial opportunity for the medical community and investors to engage with the cutting-edge science aimed at transforming oncology.

For continuous updates about TuHURA Biosciences and its initiatives, visit www.tuhurabio.com and follow them on social media platforms such as Facebook, X, and LinkedIn.

Conclusion

With a commitment to overcoming cancer's toughest challenges, TuHURA Biosciences stands poised to lead significant advancements in immuno-oncology. The insights shared at the Canaccord Genuity Growth Conference could revolutionize the treatment protocols of the future, making this an event not to be missed.